These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21063845)

  • 1. Effect of Mad2 on paclitaxel-induced cell death in ovarian cancer cells.
    Hao X; Zhou Z; Ye S; Zhou T; Lu Y; Ma D; Wang S
    J Huazhong Univ Sci Technolog Med Sci; 2010 Oct; 30(5):620-5. PubMed ID: 21063845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30.
    Fu Y; Ye D; Chen H; Lu W; Ye F; Xie X
    Gynecol Oncol; 2007 Apr; 105(1):66-73. PubMed ID: 17234259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
    Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
    J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint.
    Sudo T; Nitta M; Saya H; Ueno NT
    Cancer Res; 2004 Apr; 64(7):2502-8. PubMed ID: 15059905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.
    Bates M; Spillane CD; Gallagher MF; McCann A; Martin C; Blackshields G; Keegan H; Gubbins L; Brooks R; Brooks D; Selemidis S; O'Toole S; O'Leary JJ
    PLoS One; 2020; 15(12):e0243715. PubMed ID: 33370338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro.
    Prencipe M; Fitzpatrick P; Gorman S; Tosetto M; Klinger R; Furlong F; Harrison M; O'Connor D; Roninson IB; O'Sullivan J; McCann A
    Br J Cancer; 2009 Dec; 101(11):1900-8. PubMed ID: 19935801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preliminary study of the prohibitin protein and paclitaxel resistance in ovarian cancer].
    Tang J; Cao L; Yi H; Tang C
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Dec; 37(12):1221-7. PubMed ID: 23281375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depression of MAD2 inhibits apoptosis of gastric cancer cells by upregulating Bcl-2 and interfering mitochondrion pathway.
    Du Y; Yin F; Liu C; Hu S; Wang J; Xie H; Hong L; Fan D
    Biochem Biophys Res Commun; 2006 Jul; 345(3):1092-8. PubMed ID: 16714000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depression of MAD2 inhibits apoptosis and increases proliferation and multidrug resistance in gastric cancer cells by regulating the activation of phosphorylated survivin.
    Wang L; Yin F; Du Y; Chen B; Liang S; Zhang Y; Du W; Wu K; Ding J; Fan D
    Tumour Biol; 2010 Jun; 31(3):225-32. PubMed ID: 20440596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silencing Wnt2B by siRNA interference inhibits metastasis and enhances chemotherapy sensitivity in ovarian cancer.
    Wang H; Fan L; Xia X; Rao Y; Ma Q; Yang J; Lu Y; Wang C; Ma D; Huang X
    Int J Gynecol Cancer; 2012 Jun; 22(5):755-61. PubMed ID: 22635028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of spindle checkpoint on Akt2-mediated paclitaxel-resistance in A2780 ovarian cancer cells.
    Zhou T; Bao Y; Ye S; Weng D; Chen G; Lu Y; Ma D; Wang S
    J Huazhong Univ Sci Technolog Med Sci; 2010 Apr; 30(2):206-11. PubMed ID: 20407875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of REST and TUBB3 in ovarian cancer and its relationship to paclitaxel resistance.
    Gao S; Zhao X; Lin B; Hu Z; Yan L; Gao J
    Tumour Biol; 2012 Oct; 33(5):1759-65. PubMed ID: 22684772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3β/β-catenin signalling.
    Zhang K; Song H; Yang P; Dai X; Li Y; Wang L; Du J; Pan K; Zhang T
    Cell Prolif; 2015 Apr; 48(2):249-58. PubMed ID: 25643607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Hec1 expression enhances the sensitivity of human ovarian cancer cells to paclitaxel.
    Mo QQ; Chen PB; Jin X; Chen Q; Tang L; Wang BB; Li KZ; Wu P; Fang Y; Wang SX; Zhou JF; Ma D; Chen G
    Acta Pharmacol Sin; 2013 Apr; 34(4):541-8. PubMed ID: 23474708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of hypoxia on the chemotherapeutic sensitivity of human ovarian cancer cells to paclitaxel and its mechanism].
    Huang L; Zhang QH; Ao QL; Xing H; Lu YP; Ma D
    Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):96-100. PubMed ID: 17645840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK5RAP2 is required for spindle checkpoint function.
    Zhang X; Liu D; Lv S; Wang H; Zhong X; Liu B; Wang B; Liao J; Li J; Pfeifer GP; Xu X
    Cell Cycle; 2009 Apr; 8(8):1206-16. PubMed ID: 19282672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of Mad2 induces osteosarcoma cell apoptosis-involved Rad21 cleavage.
    Yu L; Guo W; Zhao S; Tang J; Liu J
    J Orthop Sci; 2011 Nov; 16(6):814-20. PubMed ID: 21901524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of MAD2 expression to mitotic checkpoint control in ovarian cancer cells.
    Wang X; Jin DY; Ng RW; Feng H; Wong YC; Cheung AL; Tsao SW
    Cancer Res; 2002 Mar; 62(6):1662-8. PubMed ID: 11912137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism.
    Poruchynsky MS; Giannakakou P; Ward Y; Bulinski JC; Telford WG; Robey RW; Fojo T
    Biochem Pharmacol; 2001 Dec; 62(11):1469-80. PubMed ID: 11728383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of siltuximab on the interleukin-6/Stat3 signaling pathway in ovarian cancer].
    Guo YQ; Lu P; Duan ZF; Zhang Z
    Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):854-9. PubMed ID: 21211286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.